Eligible to autologous stem-cell transplantation (first line treatment) |
CyBorD (cyclophosphamide + bortezomib + dexamethasone) |
|
Lenalidomide + dexamethasone |
|
VTD (bortezomib + thalidomide + dexamethasone) |
|
Lenalidomide maintenance therapy after autologous stem cell transplant |
|
Transplant-ineligible patients (first line treatment) |
Daratumumab + lenalidomide + dexamethasone |
|
Lenalidomide + dexamethasone |
|
CyBorD (cyclophosphamide + bortezomib + dexamethasone) |
|
Daratumumab + VMP (bortezomib + melphalan + prednisone) |
|
VMP (bortezomib + melphalan + prednisone) |
|
VTD (bortezomib + thalidomide + dexamethasone) |
|
Bortezomib + dexamethasone |
|
Relapse/refractory (2nd line and more) |
KRd (carfilzomib + lenalidomide + dexamethasone) (2nd to 4th line) |
|
Kd (carfilzomib + dexamethasone) (2nd to 4th line) |
|
Lenalidomide + dexamethasone |
|
DRd (daratumumab + lenalidomide + dexamethasone) |
|
DVd (daratumumab + bortezomib + dexamethasone) |
|
IRd (ixazomib + lenalidomide + dexamethasone) (2nd to 4th line) |
|
Pomalidomide + dexamethasone (3rd line and more) |
|